Amigo AI's $11M Plan to Train AI Agents Like Human Doctors

NEW YORK, NY – March 10, 2026 – Amigo AI, a company pioneering a new frontier in healthcare technology, has secured an $11 million Series A funding round to advance its mission of training patient-facing clinical AI agents with the same rigor as human doctors. The investment, led by prominent venture capital firm Madrona with participation from Optum Ventures, brings Amigo's total capital raised to $17 million.

The funding arrives as the healthcare industry grapples with a critical shortage of clinicians while simultaneously facing a surge in demand for technology-enabled care. Amigo AI positions itself at the nexus of this challenge, developing autonomous AI agents designed to handle high-value clinical workflows, from patient intake and triage to personalized care navigation and round-the-clock support. By automating these interactions, the company aims to expand the capacity of existing care teams and improve patient outcomes on a global scale.

A New Standard for Clinical Safety

At the heart of Amigo AI's strategy is a deep-seated focus on trust and safety, a non-negotiable element in a field where errors can have life-or-death consequences. The company is betting that for AI to be truly accepted by patients and providers, it must first prove its reliability beyond any doubt.

"We train our agents like doctors because mistakes can cost lives in healthcare,” said Ali Khokhar, Founder and CEO of Amigo, in a statement. "No agent should interact with a real patient until it's been rigorously trained and proven safe."

This philosophy is built upon what Amigo calls a "simulation-first" approach. The company has developed three core innovations to ensure its AI meets the highest clinical standards. First is an "agent brain" modeled on the cognitive processes of a physician, enabling it to recall a patient's complete history and, crucially, recognize when a situation requires escalation to a human clinician.

Second, and perhaps most distinctively, is a training program the company likens to a medical residency. Every Amigo agent undergoes a "digital residency," training across millions of simulated patient scenarios tailored to the specific population of the healthcare practice it will serve. These simulations deliberately over-index on adversarial situations and rare edge cases, pushing the AI to learn and improve across metrics like diagnostic accuracy, empathy, and harm prevention until it achieves a 100% safety pass rate. The company reports that its agents have already completed over three million patient encounters worldwide in the last six months with zero safety incidents.

"Amigo is addressing one of the hardest problems in healthcare AI, deploying autonomous systems where trust and safety are non-negotiable," noted Sabrina Albert, Partner at Madrona. "Their simulation-first approach to clinical safety positions them to define the standard for patient-facing AI."

The third innovation is a connected platform where multiple AI agents can collaborate like a human care team, sharing unified patient context in real time to ensure safe handoffs and eliminate information loss. This integrated system allows healthcare organizations to automate complex, team-based workflows without the fragmentation often seen with single-purpose point solutions.

Addressing a Looming Healthcare Crisis

The urgency for solutions like Amigo AI is underscored by a dire global forecast. The World Health Organization and other bodies project a shortfall of up to 11 million healthcare workers by 2030, a crisis exacerbated by clinician burnout from the COVID-19 pandemic and the rising care demands of an aging population.

This widening gap between the supply of healthcare professionals and the demand for their services is where AI augmentation shows its greatest promise. Rather than replacing human doctors, clinical agents can act as a force multiplier, handling routine and administrative tasks to free up clinicians to focus on complex patient care and human-to-human interaction.

Dr. Jay Shah, recently appointed as Amigo's Chief Medical Advisor and currently the Chief of the Medical Staff at Stanford Health Care, brings a frontline perspective to the company's mission. "In my 23 years of practicing medicine, I've watched the demand for care outpace our ability to deliver it," Dr. Shah stated. "Amigo's approach of training agents with the same rigor we expect of clinicians means they can operate at the standard I've seen at Stanford, Columbia, and MD Anderson."

By deploying agents for tasks like initial patient intake, symptom triage, and answering common questions, healthcare systems can expand access, reduce wait times, and provide continuous support outside of normal clinic hours, ultimately making the entire system more efficient and resilient.

Strategic Capital and Market Momentum

The investors backing Amigo AI signal strong confidence not only in the company's technology but also in its strategic position within the evolving healthcare landscape. Lead investor Madrona has a long history of backing transformative AI companies and has recently focused on "intelligent applications" that solve domain-specific problems. Their investment reflects a belief that the next wave of value in AI will come from agentic systems that can operate effectively within specialized, high-stakes environments like healthcare.

The participation of Optum Ventures, the venture arm of health services giant Optum, is particularly significant. As part of UnitedHealth Group, Optum has a vast network and a deep-seated interest in leveraging technology to improve care delivery and reduce costs. An investment from Optum Ventures often provides portfolio companies with invaluable strategic guidance and a potential pathway to scale within one of the world's largest healthcare ecosystems. Their involvement suggests a strong alignment between Amigo's safety-conscious approach and the principles of responsible AI deployment championed by major industry players.

This financial backing is further bolstered by favorable regulatory tailwinds. Government initiatives, such as the Centers for Medicare & Medicaid Services (CMS) models promoting technology-enabled care, are creating new reimbursement pathways and incentives for providers to adopt digital health solutions. These shifts are lowering barriers to adoption and fueling market demand for platforms that can deliver care more efficiently and at scale.

The Technology in Practice

Beyond the theoretical promise, Amigo AI is already demonstrating its value in real-world clinical settings. The platform is currently being used by healthcare organizations globally, including digital health company Eucalyptus and providers like Diverge Health and The Care Clinic.

A key factor in its adoption is its enterprise-ready architecture. The platform is designed for seamless integration with all major Electronic Health Record (EHR) systems, including Epic, Oracle Health, and Athenahealth. This interoperability is critical for ensuring that the AI agents have access to the comprehensive patient data needed to function safely and effectively.

Furthermore, the company has built its platform to be fully compliant with stringent data security and privacy regulations, holding HIPAA, SOC 2 Type II, and GDPR certifications. This commitment to security is essential for earning the trust of large healthcare enterprises and their patients. The platform's ability to operate in over 100 languages also highlights its design for global scale, enabling partners to deploy custom-built agents that can serve diverse patient populations. This combination of rigorous safety training, strategic backing, and enterprise-grade deployment capabilities positions Amigo AI to play a significant role in shaping the future of AI-driven healthcare.